Other News To Note
Wednesday, October 17, 2012
BioLineRx Ltd., of Jerusalem, said a recent analysis of data from its Phase IIb EAGLE trial testing orally available GABA-enhanced antipsychotic BL-1020 in schizophrenia indicated that the drug demonstrated a significant increase in efficacy at improving cognitive impairment associated with the condition, as compared to the original analysis of the study.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.